Contributions
Abstract: P882
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Cognitive dysfunction is present in a majority of patients with multiple sclerosis (MS). However, cognitive testing is infrequently performed in the clinical setting due to either time, personnel constraints, or perceived stress of current tests such as Paced Auditory Serial Addition Test (PASAT). Additionally, these tests primarily assess subcortical processing. Within the past decade there has been increased appreciation of both cortical demyelinating inflammatory lesions and cortical atrophy in both relapsing and progressive MS. The clinical correlates of this cortical pathology may not be fully captured with current cognitive tests. Cognivue, is a computer based cognitive test that was recently FDA-approved for evaluation of early signs of dementia in persons over the age of 55. Cognivue takes only 10 minutes to complete and is able to test both cortical and subcortical cognitive domains.
Objective: The primary objective was to conduct a pilot study comparing patients with clinically stable MS and healthy controls using PASAT, SDMT and Cognivue.
Methods: 23 patients with MS and 9 healthy controls between 18 and 50 years were enrolled. Baseline testing included an Expanded Disability Scale (EDSS), Perceived Deficits Questionnaire (PDQ-5), PASAT, SDMT and Cognivue.
Results: Preliminary cross-sectional data show significant differences between patients with MS and healthy controls on PASAT (Z scores -0.15 vs 0.25, p=0.0033), SDMT (Z scores -0.920 vs 1.31, p=0.0001) and composite Cognivue score (83.1 vs 92.7, p=0.02). Additionally, two Cognivue component tasks, adaptive motor (52.2 vs 74, p=0.0004) and motion discrimination (73.3 vs 82.31, p=0.02) were significantly different between patients with MS and healthy controls.
Conclusion: These results suggest that Cognivue, a cognitive test that can be easily implemented in the clinical setting, may be able to detect cognitive dysfunction in MS. Further, specific Cognivue domain performance may show a profile of cognitive dysfunction that is characteristic of patients with MS.
Disclosure: Dr. Smith receives training support from the National Multiple Sclerosis Society Sylvia Lawry Physician Fellowship grant.
Dr. Goodman received personal compensation for consulting from the following commercial entities: Abbvie, Acorda Therapeutics, Atara, Bayer, Biogen Idec, Genentech, Sanofi Genzyme, Novartis, Purdue, Teva.
Dr. Goodman´s employer, the University of Rochester, received research support for conducting clinical trials from the following commercial entities: Acorda Therapeutics, Avanir, Biogen-Idec, EMD-Serono, Novartis, Ono, Roche, Sanofi Genzyme, Sun Pharma, Teva.
Dr. Duffy is Founder, President, and Chief Executive Officer of Cerebral Assessment Systems, manufacturer of Cognivue.
Abstract: P882
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Cognitive dysfunction is present in a majority of patients with multiple sclerosis (MS). However, cognitive testing is infrequently performed in the clinical setting due to either time, personnel constraints, or perceived stress of current tests such as Paced Auditory Serial Addition Test (PASAT). Additionally, these tests primarily assess subcortical processing. Within the past decade there has been increased appreciation of both cortical demyelinating inflammatory lesions and cortical atrophy in both relapsing and progressive MS. The clinical correlates of this cortical pathology may not be fully captured with current cognitive tests. Cognivue, is a computer based cognitive test that was recently FDA-approved for evaluation of early signs of dementia in persons over the age of 55. Cognivue takes only 10 minutes to complete and is able to test both cortical and subcortical cognitive domains.
Objective: The primary objective was to conduct a pilot study comparing patients with clinically stable MS and healthy controls using PASAT, SDMT and Cognivue.
Methods: 23 patients with MS and 9 healthy controls between 18 and 50 years were enrolled. Baseline testing included an Expanded Disability Scale (EDSS), Perceived Deficits Questionnaire (PDQ-5), PASAT, SDMT and Cognivue.
Results: Preliminary cross-sectional data show significant differences between patients with MS and healthy controls on PASAT (Z scores -0.15 vs 0.25, p=0.0033), SDMT (Z scores -0.920 vs 1.31, p=0.0001) and composite Cognivue score (83.1 vs 92.7, p=0.02). Additionally, two Cognivue component tasks, adaptive motor (52.2 vs 74, p=0.0004) and motion discrimination (73.3 vs 82.31, p=0.02) were significantly different between patients with MS and healthy controls.
Conclusion: These results suggest that Cognivue, a cognitive test that can be easily implemented in the clinical setting, may be able to detect cognitive dysfunction in MS. Further, specific Cognivue domain performance may show a profile of cognitive dysfunction that is characteristic of patients with MS.
Disclosure: Dr. Smith receives training support from the National Multiple Sclerosis Society Sylvia Lawry Physician Fellowship grant.
Dr. Goodman received personal compensation for consulting from the following commercial entities: Abbvie, Acorda Therapeutics, Atara, Bayer, Biogen Idec, Genentech, Sanofi Genzyme, Novartis, Purdue, Teva.
Dr. Goodman´s employer, the University of Rochester, received research support for conducting clinical trials from the following commercial entities: Acorda Therapeutics, Avanir, Biogen-Idec, EMD-Serono, Novartis, Ono, Roche, Sanofi Genzyme, Sun Pharma, Teva.
Dr. Duffy is Founder, President, and Chief Executive Officer of Cerebral Assessment Systems, manufacturer of Cognivue.